INCIDENCE OF BRCA IN PATIENTS WITH PRIMARY OR PLATINUM SENSITIVE RECURRENT OVARIAN CANCER

Protocol ID:
AGO-TR 1 (BRCA-Screening)

A Project of the AGO Study Group

AGO Study Group
Kaiser-Friedrich-Ring 71
65185 Wiesbaden
Germany

Version V01F / 11-Aug-2014

In Cooperation with
Center for Hereditary Breast and Ovarian Cancer
University of Cologne, Germany
Coordinating Investigator for the AGO Study Group

Philipp Harter, MD
Klinik für Gynäkologie & Gynäkologische Onkologie
Kliniken Essen - Mitte
Evang. Huysens Stiftung/Knappschaft GmbH
Henricistraße 92
45136 Essen, Germany

Study offices
AGO Study Group
Kaiser-Friedrich-Ring 71
65185 Wiesbaden, Germany
Moltkeplatz 63
45138 Essen, Germany

Biometrics
Alexander Reuß
Koordinierungszentrum für Klinische Studien (KKS) Marburg
Philipps-Universität Marburg
Karl-von-Frisch-Straße 4
35043 Marburg, Germany

Data Management
Koordinierungszentrum für Klinische Studien (KKS) Marburg
Philipps-Universität Marburg
Karl-von-Frisch-Straße 4
35043 Marburg, Germany

Monitoring
Schantl Pharma Service GmbH
Herderstraße 16
65185 Wiesbaden, Germany
Persons In charge of study
Coordinating Investigator for the AGO Study Group

Philipp Harter, MD
Date
Klinik für Gynäkologie & Gynäkologische Onkologie
Kliniken Essen - Mitte
Evang. Huysens Stiftung/Knappschaft GmbH
Henricistraße 92
45136 Essen, Germany

Biometrics:

Alexander Reuß
Date
Koordinierungszentrum für Klinische Studien Marburg
Philipps-Universität Marburg
Karl-von-Frisch-Straße 4
35043 Marburg, Germany
Table of Contents

1 Protocol authorization .................................................................................................................. 6

2 Summary ........................................................................................................................................ 7

3 Introduction ......................................................................................................................................... 10

3.1 Ovarian Cancer and its Treatment ........................................................................................... 10

3.2 BRCA mutation in Ovarian Cancer ........................................................................................... 10

4 Rationale ...................................................................................................................................... 11

5 Objectives ..................................................................................................................................... 11

6 Study Design ................................................................................................................................... 12

6.1 Patient selection ....................................................................................................................... 12

6.2 Patients’ registration ................................................................................................................. 12

6.3 Patients’ evaluation .................................................................................................................. 12

6.3.1 Baseline Evaluation ......................................................................................................... 12

6.3.2 Firstline Treatment Evaluation ......................................................................................... 12

6.3.3 Further Treatment Evaluation .......................................................................................... 13

6.3.4 Follow-up Evaluation ....................................................................................................... 13

6.4 Duration of Study ...................................................................................................................... 13

7 Sample Collection and Procedures .......................................................................................... 13

7.1 Archival Tumor Samples .......................................................................................................... 13

7.2 Blood Sampling ........................................................................................................................ 13

7.3 Sample Shipment ..................................................................................................................... 14

8 Determination of Safety ............................................................................................................. 14

9 Statistical Considerations .......................................................................................................... 14

10 Data Management ....................................................................................................................... 14

10.1 Patient Identification List and Patient ID .............................................................................. 14

10.2 Data entry and documentation ............................................................................................. 14

10.3 Storage of study documents ................................................................................................ 15

11 Quality assurance ....................................................................................................................... 15

12 Ethical principles ........................................................................................................................ 15

12.1 Ethics committee ..................................................................................................................... 15

12.2 Informing patients .................................................................................................................. 16

12.3 Informed consent to participation ......................................................................................... 16

12.4 Use, storage and transmission of data ................................................................................ 16
13 Legal and administrative regulations ................................................................................. 16

13.1 Financing ......................................................................................................................... 16

13.2 Patient insurance ............................................................................................................. 16

13.3 Final report and publication ........................................................................................... 16

13.4 Adherence to protocol and protocol amendments ......................................................... 16

14 List of Abbreviations .......................................................................................................... 17

15 References .......................................................................................................................... 18
1 Protocol authorization

<table>
<thead>
<tr>
<th>Study title</th>
<th>INCIDENCE OF BRCA IN PATIENTS WITH PRIMARY OR PLATINUM SENSITIVE RECURRENT OVARIAN CANCER. AGO-TR 1 / BRCA-SCREENING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version</td>
<td>V01F 11-Aug-2014</td>
</tr>
</tbody>
</table>

**Principal Investigator**

place, date

signature

name (in block letters)

**Declaration**

With my above-given signature I confirm that the present study is performed in agreement with the most recent version of the declaration of Helsinki and "ICH Guideline on Good Clinical Practice".
2 Summary

TITEL

BRCA-Screening in Ovarian Cancer
Incidence of BRCA in patients with primary or platinum sensitive recurrent ovarian cancer.
(Protocol ID: AGO-TR 1)

SPONSOR

AGO Research GmbH, AGO Study Group

COOPERATION

Center for Hereditary Breast and Ovarian Cancer, University of Cologne, Germany

PROJECT LEAD

Philipp Harter, MD, Essen, Germany

INDICATION

Primary diagnosis or platinum-sensitive recurrence in patients with epithelial invasive ovarian cancer.

RATIONALE

About 15% of patients with first diagnosis of ovarian cancer are estimated to have a germline mutation regarding BRCA1/2. Whilst BRCA-status was in the past a prognostic factor regarding own outcome of existing breast and/or ovarian cancer and risk regarding secondary malignancy (including potential consequences for relatives) it has now changed to a predictive marker regarding treatment with PARP-inhibitors like Olaparib (Ledermann et al. New Engl J Med 2012, Ledermann et al. J Clin Oncol 2013). Unfortunately, details of the incidence of BRCA positive patients with first diagnosis and platinum sensitive recurrent ovarian cancer in the German population are not clearly defined. In addition, germline testing includes intensive counseling of the patient including their families. It might also be feasible to test paraffin embedded tumor regarding somatic BRCA mutations to define responsiveness regarding PARP-inhibition.

The aim of this prospective registration and translational research study is to evaluate the incidence of BRCA regarding germline and somatic mutations. In addition, we plan to collect tumor samples of first diagnosis and relapse (if available) to look for potential changes in the BRCA-status of the tumor.

STUDY DESIGN

Prospective, non-interventional, national, multi-center study.

NUMBER OF PATIENTS

500 consecutive patients (up to 250 +/- 10% patients with primary diagnosis and up to 250 +/- 10% patients with platinum-sensitive recurrence of ovarian cancer)

TARGET POPULATION

Adult female patients with first diagnosed or platinum-sensitive recurrent epithelial invasive ovarian cancer.
OBJECTIVES

**Primary objective:**
- Evidence of germline alterations in BRCA1/2 and other ovarian cancer predisposing genes.

**Secondary objectives:**
- Immunohistochemistry and DNA extraction from tumor samples
- Evidence of somatic alterations in BRCA1/2 and other ovarian cancer predisposing genes
- Evidence for a BRCAness tumor phenotype in ovarian cancer
- Differences of tumor samples from primary and relapsed disease
- Evaluation of patient perspectives and satisfaction regarding testing and counseling (survey)

**Translational objectives:**
- Validate the results from Pennington et al. (*Pennington et al. Clin Cancer Res 2014*)
- Evaluate predictive value of PARP-1 expression for HRD mutations
- Identify BRCA 1/2 promoter hypermethylation / epigenetic alterations in addition to genetic alterations
- Identify large rearrangements/recurrent genomic alterations via genome-wide arrayCGH analysis to describe BCRAness tumor phenotype and identify further genes
- Identify and characterize large rearrangements in BRCA1/2 with MLPA in the tumor tissue probes

**INCLUSION CRITERIA**
1. Female ovarian cancer patients aged ≥ 18 years.
2. Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer (i.e., women who have received an initial course of platinum-based chemotherapy and with no evidence of disease progression for at least 6 months after the last administration of a platinum-based regimen for initial treatment).
3. Multiple platinum based prior therapies are allowed.

**EXCLUSION CRITERIA**
1. Non-epithelial ovarian malignancy.
2. Platinum resistant or refractory disease.
3. Paraffin embedded tumor samples not available.
### INTERVENTION

None.

Clinical examinations, providing existing tumor samples, blood samples

### STUDY DURATION

Start: Q3 2014

Recruitment: N = 500 consecutive patients will be included into this study over a period of 6 months.

Follow-up: 60 months

First Patient In to Last Patient Out: Q3 2014 – Q1 2020

### VARIABLES AND OUTCOMES

#### Demographic:
- Year of Birth
- Ethnicity

#### Disease Characteristics:
- Date of first diagnosis and/or date of recurrence
- FIGO Stage, Grading, Histology

#### Medical History:
- Personal history of BRCA associated cancer
- Family history of BRCA associated cancer
- Number of platinum-based chemotherapy lines (if applicable)
- Agents, doses, number of cycles, schedules, durations (dates of first and final administration) (if applicable)

#### Sample Assessments:
- Results of the search for germline alterations in BRCA1/2 and other ovarian cancer predisposing genes
- Result of immunohistochemistry
- Results of search for somatic alterations in BRCA1/2 and other ovarian cancer predisposing genes
- Results of search for BRCAness tumor phenotype in ovarian cancer

#### Outcome:
- Progression-free survival (assessment of progression, date of progression)
- Overall survival (date of death)

### SAMPLE SIZE CALCULATION / STATISTICAL ANALYSIS

The study size is not based on formal statistical considerations. A target study size of at least 500 patients will be considered for the conduct of the study.
3 Introduction

3.1 Ovarian Cancer and its Treatment

Epithelial ovarian cancer and related malignancies represent the fifth most common cause of cancer-related death among women in Europe and the United States of America\(^1,2\). Ovarian Cancer (OC) alone is the fourth most common cause of cancer-related death in women with estimated 200,000 cases and 125,000 deaths annually worldwide. According to statistics from the Robert-Koch-Institute, in Germany 2010, 7,780 patients were newly diagnosed and 5,599 died from this neoplasm\(^3\).

The incidence of ovarian cancer increases with age and is most prevalent in the eighth decade of life. More than 70% of the patients are diagnosed with advanced disease and less than 40% of women with ovarian cancer are cured\(^4,5\). Unfortunately, effective screening methods are lacking\(^6\).

The standard therapy for advanced ovarian cancer consists of radical debulking surgery followed by post-operative platinum-based first-line chemotherapy. Since 1996, platinum and paclitaxel combination therapy has become the standard-of-care first-line chemotherapy regimen\(^7\). Worldwide, the use of carboplatin has replaced that of cisplatin because of carboplatin's superior tolerability profile together with equal effectiveness. However, the success of this approach is limited and approximately 70% of patients fail to achieve complete responses, or eventually relapse, after a varying disease-free interval.

Should a relapse or a progression after first-line therapy occur, cure of the disease is rarely possible. In this case, second-line chemotherapy is usually offered, with a palliative intent. Recurrence-free interval influences the choice of possible second-line chemotherapy, specifically the value of platinum re-exposure\(^8-10\) and is of prognostic importance for the ongoing course of the illness\(^11\). Patients with ovarian cancer who developed recurrence >6 months after completion of first-line platinum chemotherapy are characterized as having platinum-sensitive disease.

For patients with platinum-sensitive disease, response rates of 20% to 30% may be seen with platinum re-treatment in those with a platinum-free interval if 6 to 12 months. In those patients with treatment-free intervals >12 months, response rates in the range of 30% to 70% may be seen, and some patients may benefit from durable second remissions.

Carboplatin in combination with gemcitabine +/- bevacizumab, pegylated liposomal doxorubicin or paclitaxel represents the main treatment options for patients with relapsed platinum-sensitive disease, being repeated as long as the patients remains platinum-sensitive\(^12\).

3.2 BRCA mutation in Ovarian Cancer

An important risk factor for ovarian cancer is genetic predisposition with BRCA1 and BRCA2 mutations (i.e., gBRCAm) which account for the majority of hereditary ovarian cancers. If a lifetime risk for ovarian cancer among women in the general population is estimated to be 1.4%, a woman with BRCA1 or BRCA2 deleterious mutation has a lifetime risk of 15% to 40%\(^13\). BRCA mutated ovarian cancer patients can also develop ovarian cancer earlier in their life than those without the mutation. Deficiency in BRCA ultimately leads to the accumulation of genetic alterations as a result of the failure of cells arrest and repair DNA damage or to undergo apoptosis, resulting in tumorigenesis. If all ovarian cancer patients underwent gBRCA testing, current estimates indicate that 13% to 14% of the overall ovarian cancer population would have gBRCA1/2 mutations, and the proportion of patients with gBRCA mutations may be as high as 22% in patients with high-grade serous ovarian cancer (HGSOC). In addition, a population of ovarian cancer patient whose tumors harbor BRCA1 and BRCA2 mutations that are not detected in the germline (approx. 7 %) also exist and are defined as somatic BRCA mutations (tBRCAm).
Patients with BRCA-mutated ovarian cancer currently have identical treatment options as sporadic ovarian cancer patients. They seem to have better prognosis compared with the overall relapsed ovarian cancer patient population but the pattern of disease is similar, with patients eventually dying from their disease. Ovarian cancer patients with BRCA mutation represent a small, well defined and medically recognized subpopulation for whom, despite the potential for personalized healthcare, no targeted treatment currently exists.

4 Rationale

About 15% of patients with first diagnosis of ovarian cancer are estimated to have a germline mutation regarding BRCA1/2. Whilst BRCA status was in the past a prognostic factor regarding own outcome of existing breast and/or ovarian cancer and risk regarding secondary malignancy (including potential consequences for relatives) it has now changed to a predictor marker regarding treatment with PARP-inhibitors like Olaparib\textsuperscript{14,15}. Unfortunately, details of the incidence of BRCA positive patients with first diagnosis and platinum sensitive recurrent ovarian cancer in the German population are not clearly defined. In addition, germline testing includes intensive counseling of the patient including their families. It might also be feasible to test tumor samples regarding somatic BRCA mutations to define responsiveness regarding PARP-inhibition.

The aim of this prospective registration and translational research study is to evaluate the incidence of BRCA regarding germline and somatic mutations. In addition, we plan to collect tumor samples of first diagnosis and relapse (if available) to look for potential changes in the BRCA-status of the tumor.

5 Objectives

Primary objective:
- Evidence of germline alterations in BRCA1/2 and other ovarian cancer predisposing genes

Secondary objectives:
- Immunohistochemistry and DNA extraction from tumor samples
- Evidence of somatic alterations in BRCA1/2 and other predisposing genes
- Evidence for a BRCAness tumor phenotype in ovarian cancer
- Differences of tumor samples from primary and relapsed disease
- Evaluation of patient perspectives and satisfaction regarding testing and counseling (survey)

Translational objectives:
- Validate the results from Pennington et al.\textsuperscript{16}
- Evaluate predictive value of PARP-1 expression for HRD mutations
- Evaluate predictive value of PARP-1 expression for HRD mutations
- Identify BRCA 1/2 promoter hypermethylation / epigenetic alterations in addition to genetic alterations
- Identify large rearrangements/recurrent genomic alterations via genome-wide arrayCGH analysis to describe BCRAness tumor phenotype and identify further genes
- Identify and characterize large rearrangements in BRCA1/2 with MLPA in the tumor tissue probes
6 Study Design

6.1 Patient selection

The patient must fulfill the following inclusion and exclusion criteria.

**Inclusion criteria:**
- Female ovarian cancer patients aged \( \geq 18 \) years.
- Women with first diagnosis of epithelial ovarian cancer OR women diagnosed with platinum-sensitive recurrent ovarian cancer (i.e., women who have received an initial course of platinum-based chemotherapy and with no evidence of disease progression for at least 6 months after the last administration of a platinum-based regimen for initial treatment).
- Multiple platinum based prior therapies are allowed.

**Exclusion criteria:**
- Non-epithelial ovarian malignancy.
- Platinum resistant or refractory disease.
- Paraffin embedded tumor samples and slides not available.

6.2 Patients’ registration

Following the signature of an informed consent and the validation of the inclusion and exclusion assessments, eligible patients will be registered by fax using the CRF for registration. Registration Fax should be send to

KKS Marburg  
Philipps University  
Karl-von-Frisch-Straße 4  
35043 Marburg  
Germany

Fax No.: +49 (0) 6421-2866516

6.3 Patients’ evaluation

6.3.1 **Baseline Evaluation**

Patients who have signed the informed consent will undergo the following evaluations
- Age / Ethnicity
- Height / Weight / ECOG
- Medical Gynecological History
- Familial Medical History relevant for BRCA screening
- Lab Values (only total Bilirubin and Creatinine, if not be done in the last 3 months before registration)

6.3.2 **Firstline Treatment Evaluation**

For patients included with primary diagnosis the following items should be documented
- Tumor Histology
- Firstline Treatment including Maintenance Therapy
- Patient Status
6.3.3 Further Treatment Evaluation
For patients included with platinum-sensitive recurrent disease only the following items should be documented:
- Tumor Histology
- Firstline and further Treatments including Maintenance Therapy
- Patient Status

For patients included with primary diagnosis and a platinum-sensitive recurrence occurred data for both statuses should be documented.

6.3.4 Follow-up Evaluation
Follow-up visits will include:
- Date death / alive,
- Date of any recurrence / progression,
- New cancer treatment since last visit (yes/no),
- Diagnosis of next malignancy (yes/no).

Follow-up visits should be done every 12 months after date of registration.

6.4 Duration of Study
The study is planned to start Q3 2014 with respect to first patient in (FPI) including a registration period of 6 months. Each patient will be followed 5 years or until death (whichever occurs first).

7 Sample Collection and Procedures
The samples and data from this research will be coded and not labelled with any personal details. Each sample will be identified with the study code and patient enrolment number. In this way biomarker data may be correlated with clinical data, samples destroyed after analysis. However, only the investigator will be able to link the biomarker sample to the individual patient. The samples and any results will remain the responsibility of the sponsor.

The sponsor will not provide biomarker results to patients, their family members, any insurance company, an employer, study investigator, general physician or any third party unless required to do so by law. The patient’s samples will not be used for any other purpose other than those described in the protocol.

The exception to the above is the gBRCA result. This result will be provided to the investigator and will be collected as part of the patient’s demography and medical history details.

7.1 Archived Tumor Samples
For all enrolled patient, archived tumor samples must be collected for BRCA and further genetic testing. 8 tumor slides should be sent to the University of Cologne, Center for Hereditary Breast and Ovarian Cancer, Germany. Tumor slides should be sending to the University of Cologne during 3 weeks after registration.

7.2 Blood Sampling
After registration 20mL blood collected in EDTA tubes for BRCA and further genetic testing should be send directly after collection to the University of Cologne, Center for Hereditary Breast and Ovarian cancer, Germany.
7.3 Sample Shipment

Each sample (tumor slides and blood) will be sent directly after collection to:

Universitätsklinik Köln
Zentrum für Familienbrust- und Eierstockkrebs
Kerpener Straße 34, Gebäude 47, 8. Etage, Raum 8.016
z. Hd. Frau Sandra Körber / Herr Dr. Jan Hauke
50931 Köln
Germany
Phone: +49 (0) 221 478 86682 or +49 (0) 221 478 98570
Fax: +49 (0) 221 478 87016

8 Determination of Safety

Only spontaneously occurred adverse events in relationship with a substance of AstraZeneca should be documented. These adverse events (“UAWs”) should be sending directly to AstraZeneca GmbH, Abteilung für Arzneimittelsicherheit, Tinsdaler Weg 183, 22880 Wedel, Germany.

9 Statistical Considerations

The study size is not based on formal statistical considerations. A target study size of at least 500 patients will be considered for the conduct of the study and is considered representative to answer the study objectives.

No statistical hypothesis applies.

10 Data Management

10.1 Patient Identification List and Patient ID

A patient identification list has to be handled by the investigators. In this list the pseudonymized patient ID is connected with the data to identify the patient unmistakably. The patient identification list is filed in the investigator site file (ISF). The pseudonymized patient ID is combined from the AGO center ID and a sequencing number of the patient starting with 001. This unique patient ID is used for all documentation on electronic case report form (eCRF) and DCF.

10.2 Data entry and documentation

The investigator is responsible for the performance of the study in accordance to ICH GCP guidelines and the study protocol as well as the correct data entry to the corresponding eCRF. The data are documented with the EDC (electronic data capture) system MACRO at KKS Marburg, Germany. The data are entered directly via web browser (Internet Explorer, Firefox or Google Chrome) to the eCRF and are transferred via SSL (128-bit encryption) to the central database. Detailed requirement for using EDC are specified in an EDC Manual.

In order to use the EDC system all staff who are entering and monitoring data are provided with training materials and required documentation by KKS Marburg, Germany. Every person who is using the EDC system has to complete a registration form to confirm that he/she has received the training material and has been trained for data entry. KKS provides a test database for training of data entry.

All clinical data which are collected during the study and the BRCA status have to be documented in the eCRF by authorized person according to the personal log. The participation of the patient in the study has to be documented in the patient record (study title, start and end of study).
The EDC system MACRO has an implemented audit trail. This assures that any documentation and/or changes to database items are traceable anytime. The personal log with signature, name and mnemonic of persons who are authorized to enter data to the eCRF is archived in the investigator site file (ISF) and the trial master file (TMF). Changes and corrections can only be made by persons who are documented in the TMF and who have access to the system with user specific access rights.

Users with monitoring function are not able to enter or change data. They have the possibility to view the data write protected (review function) and they can raise discrepancies and/or SDV marks in case of queries. Discrepancies which appear at data management are forwarded to the responsible monitor.

10.3 Storage of study documents

Originals of all central study documents will be kept in the study office for a period of 10 years after preparation of the publication.

The investigator keeps accrued administrative documents (correspondence with ethic committee, study coordinators, central study office), the patient identification list, signed informed consent and general study documents (protocol, amendments) for the above mentioned period.

Original data of study patients (medical records) must be stored according to the archiving period valid at the respective study site, but not less than 15 years.

11 Quality assurance

In order to guaranty the authenticity and credibility of the data in accordance with ICH GCP, AGO will set up an assurance quality program that includes:

- management of the study according to the AGO SOPs
- quality control of the data provided by the investigator/site is performed by the study monitor whose role is:
  - to match and check the consistency of the data reported in the eCRF with respect to the source documents,
  - to ensure that safety and rights of the study patient are being protected,
  - to ensure that the study is conducted in accordance with the currently approved protocol and any other study agreements and ICH GCP

The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.

12 Ethical principles

This study is performed in accordance with the most current revision of the Declaration of Helsinki.

12.1 Ethics committee

Study protocol, patient information and informed consent will be submitted each local ethics committee of every participating center. The study will only be started in a center after being approved by the ethics committee.

The co-coordinating investigators will inform the ethics committee about any changes in the study protocol which could interfere with the patient’s safety. Furthermore, the committee will be informed of the planned or premature end of the study. The investigators are obliged to consult their competent ethics committee and to wait for approval before including patients into the study, as well as to inform their ethics committee of changes in the protocol and end of study.
12.2 Informing patients
Before enrolment in the study, the treating investigator will inform the patient about the nature of the study, its aims, expected advantages as well as possible risks.

12.3 Informed consent to participation
Each patient must consent in writing to participate in the study. The patient must be given enough time and opportunity to decide on participation and to clarify queries before the beginning of documentation of the study.

The informed consent will be signed by both patient and treating investigator. If the patient is not able to sign herself, oral information and consent have to be confirmed by the signature of a witness.

Layout and text should be adapted according the requirements of local Ethics Committee by the sponsor. On request, the final forms have to be submitted to the ethics committee for review.

The original document is kept by the investigator, whereas the patient receives a copy.

12.4 Use, storage and transmission of data
Patients will be informed on the fact that their disease-related data will be stored in a pseudonymous form and used for scientific analyses (publications, reports to sponsors). Patients have the right to be informed about stored data. Consent to data access and transmission will be obtained separately from consent to participation in the study.

13 Legal and administrative regulations
The recommendations of Good Clinical Practice (see ICH-GCP: International Conference on Harmonisation - Good Clinical Practice) in the most recent version are adhered to.

13.1 Financing
This study is supported by AstraZeneca GmbH in Wedel, Germany.

13.2 Patient insurance
Not applicable.

13.3 Final report and publication
After completion of analyses, the coordinating investigator will write a publication. This report includes the clinical and statistical report as well as conclusions. The study’s results will be published irrespective of the nature of the results. The study chairmen, cooperating partners, the statistician and contributing centers will serve as (co)-authors depending absolute number of authors allowed for the respective journal.

13.4 Adherence to protocol and protocol amendments
The study protocol must be thoroughly adhered to. Any deviation must be supported by the investigator and must be documented and justified.

Changes or supplements to the study protocol can only be decided on and authorized by the coordinating principal investigator (amendment).
## 14 List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGO</td>
<td>Arbeitsgemeinschaft Gynaekologische Onkologie</td>
</tr>
<tr>
<td>BRCA</td>
<td>Breast Cancer Susceptibility Gene</td>
</tr>
<tr>
<td>CGH</td>
<td>Comparative Genomic Hybridization</td>
</tr>
<tr>
<td>DCF</td>
<td>Data Clarification Form</td>
</tr>
<tr>
<td>DNA</td>
<td>Desoxyribonucleic Acid</td>
</tr>
<tr>
<td>ECOG</td>
<td>Eastern Cooperative Oncology Group</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic Case Report Form</td>
</tr>
<tr>
<td>EDC</td>
<td>Electronic Data Capture</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene Diamine Tetraacetic Acid</td>
</tr>
<tr>
<td>FPI</td>
<td>First Patient In</td>
</tr>
<tr>
<td>gBRCA(m)</td>
<td>germline BRCA (mutation)</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>HGSOc</td>
<td>high-grade serous Ovarian Cancer</td>
</tr>
<tr>
<td>HRD</td>
<td>Homologous Recombination Repair Deficiencies</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonization</td>
</tr>
<tr>
<td>ID</td>
<td>Identification</td>
</tr>
<tr>
<td>ISF</td>
<td>Investigator Site File</td>
</tr>
<tr>
<td>KKS</td>
<td>Koordinierungszentrum für Klinische Studien</td>
</tr>
<tr>
<td>MLPA</td>
<td>Multiplex Ligation-dependent Probe</td>
</tr>
<tr>
<td>OC</td>
<td>Ovarian Cancer</td>
</tr>
<tr>
<td>PARP</td>
<td>Polyadenosine 5′diphosphoribose [poly (ADP ribose)] polymerisation</td>
</tr>
<tr>
<td>SDV</td>
<td>Source Date Verification</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedures</td>
</tr>
<tr>
<td>SSL</td>
<td>Secure Sockets Layer</td>
</tr>
<tr>
<td>tBRCAm</td>
<td>Somatic BRCA mutation</td>
</tr>
<tr>
<td>TMF</td>
<td>Trial Master File</td>
</tr>
<tr>
<td>UAW</td>
<td>Adverse Side Effects / “Unerwünschte Arzneimittelwirkung”</td>
</tr>
</tbody>
</table>
15 References


9. Gore et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36(2):207-11.


